The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT
Open accessAbstract
Background Random assignment to the intensive systolic blood pressure (SBP) arm (<120 mm Hg) in the Systolic Blood Pressure Intervention Trial (SPRINT) resulted in more rapid declines in estimated glomerular filtration rates (eGFRs) than in the standard arm (SBP < 140 mm Hg). Whether this change reflects hemodynamic effects or accelerated intrinsic kidney damage is unknown. Study Design Longitudinal subgroup analysis of clinical trial participants. Settings & Participants Random sample of SPRINT participants with prevalent chronic kidney disease (CKD) defined as eGFR < 60 mL/min/1.73 m2 by the CKD-EPI (CKD Epidemiology Collaboration) creatinine-cystatin C equation at baseline. Outcomes & Measurements Urine biomarkers of tubule function (β2-microglobulin [B2M], α1-microglobulin [A1M]), and uromodulin), injury (interleukin 18, kidney injury molecule 1, and neutrophil gelatinase-associated lipocalin), inflammation (monocyte chemoattractant protein 1), and repair (human cartilage glycoprotein 40) at baseline, year 1, and year 4. Biomarkers were indexed to urine creatinine concentration and changes between arms were evaluated using mixed-effects linear models and an intention-to-treat approach. Results 978 SPRINT participants (519 in the intensive and 459 in the standard arm) with prevalent CKD were included. Mean age was 72 ± 9 years and eGFR was 46.1 ± 9.4 mL/min/1.73 m2 at baseline. Clinical characteristics, eGFR, urinary albumin-creatinine ratio, and all 8 biomarker values were similar across arms at baseline. Compared to the standard arm, eGFR was lower by 2.9 and 3.3 mL/min/1.73 m2 in the intensive arm at year 1 and year 4. None of the 8 tubule marker levels was higher in the intensive arm compared to the standard arm at year 1 or year 4. Two tubule function markers (B2M and A1M) were 29% (95% CI, 10%−43%) and 24% (95% CI, 10%−36%) lower at year 1 in the intensive versus standard arm, respectively. Limitations Exclusion of persons with diabetes, and few participants had advanced CKD. Conclusions Among participants with CKD in SPRINT, random assignment to the intensive SBP arm did not increase any levels of 8 urine biomarkers of tubule cell damage despite loss of eGFR. These findings support the hypothesis that eGFR declines in the intensive arm of SPRINT predominantly reflect hemodynamic changes rather than intrinsic damage to kidney tubule cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, a measure of markers for AKI showed no significant increase of any markers with increased creatinine (37).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [37]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“An analysis of the Action to Control Cardiovascular Risk in Diabetes Blood Pressure (ACCORD BP) trial demonstrated that participants randomized to intensive blood pressure lowering with up to a 30% increase in serum creatinine did not have any increase in mortality or progressive kidney disease (36,37).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [37]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“An analysis of the Action to Control Cardiovascular Risk in Diabetes Blood Pressure (ACCORD BP) trial demonstrated that participants randomized to intensive blood pressure lowering with up to a 30% increase in serum creatinine did not have any increase in mortality or progressive kidney disease (36,37).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [37]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S. M., Prosek, J. M., Nádasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,392
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease
Vasan, R. S., Larson, M. G., Leip, E. P., Evans, J. C., O’Donnell, C. J., Kannel, W. B., & Levy, D. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003417 · Cited by 2,098
Wright, J. T. (2002) · JAMA · doi:10.1001/jama.288.19.2421 · Cited by 2,039
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–132 of 132
Ginsberg, C., Katz, R., Chonchol, M. B., Bullen, A. L., Raphael, K. L., Zhang, W. R., Ambrosius, W. T., Bates, J. T., Neyra, J. A., Killeen, A. A., et al. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01400220 · Cited by 1
Self-citationKhatri, R., Machart, P., & Bonn, S. (2023) · Research Square · doi:10.21203/rs.3.rs-2573385/v1 · Cited by 1
Choi, H. S., & Bae, E. H. (2025) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.25.056 · Cited by 1
Intensive BP control and incident kidney disease: what can we learn from urinary biomarkers?
Ikizler, T. A., Radhakrishnan, J., & Wong, G. (2019) · Kidney International · doi:10.1016/j.kint.2019.02.004
Choi, H. S. (2019) · Korean Journal of Medicine · doi:10.3904/kjm.2019.94.3.263
Causes of Nephrectomy in Shiraz City in 2018
Moayedi, R. Z., & Khalili, M. (2019) · Journal of Research in Urology · doi:10.30699/jru.3.1.13
We are far from achieving blood pressure goals in diabetes: Do we really want to do it?
Bonino, B., & Viazzi, F. C. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13670
Acute Kidney Injury: To Be or Not to Be: That Is the Question: It’s the Company It Keeps
Piña, I. L. (2020) · American Journal of Nephrology · doi:10.1159/000505771
The Burden of Coronary Artery Disease in Chronic Kidney Disease
Biso, S., & Ardati, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-45414-2_1
Renale relaxatie ter preventie van renale burn-out: een praktische gids
Moor, B. D., & Stas, K. (2020) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.76.22.20.062
Blutdruck bei Niereninsuffizienz
Zidek, W. (2020) · Dialyse aktuell · doi:10.1055/a-1216-4639
ความชกและปจจยสมพนธกบโรคไตจากเบาหวานในผปวยเบาหวานชนดท 2 ของโรงพยาบาลดานชาง สพรรณบร
จันทร์เปรมปรี, ก. (2021)
O’Dell, R. W. (1990) · PubMed Central
Goraya, N., & Moran, J. D. (2022) · Nephrology Self-Assessment Program · doi:10.1681/nsap.00032022
Hundemer, G. L., & Sood, M. M. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000546
SubgroupTE: Advancing Treatment Effect Estimation with Subgroup Identification
Lee, S., Liu, R., Song, W., Li, L., & Zhang, P. (2025) · ACM Transactions on Intelligent Systems and Technology · doi:10.1145/3718097
Treatment of Hypertension in Acute Kidney Injury
Kos, J., Jelaković, A., Premužić, V., Lela, I. V., & Jelaković, B. (2025) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-81292-7_14
Treatment of Hypertension in Chronic Kidney Disease
Redón, J. (2025) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-81292-7_15
Shingler, L., Tamhane, A. R., Chu, C.-H., Frey, J. A., Levitan, E. B., Judd, S. E., Bullen, A. L., Siew, E. D., Bonventre, J. V., Shlipak, M. G., et al. (2025) · medRxiv · doi:10.1101/2025.08.26.25334515
Self-citationKumar, V., Barsotti, G., Yi, Z., Sun, Z., Reghuvaran, A. C., Tanvir, E. M., Pell, J. F., Shi, H., Perincheri, S., Shaw, M. M., et al. (2025) · medRxiv · doi:10.1101/2025.10.31.25338655
Chronic Kidney Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch18
Khatri, R., Machart, P., & Bonn, S. (2024) · Figshare · doi:10.6084/m9.figshare.26714413
Khatri, R., Machart, P., & Bonn, S. (2024) · Figshare · doi:10.6084/m9.figshare.26714407
Khatri, R., Machart, P., & Bonn, S. (2024) · Figshare · doi:10.6084/m9.figshare.26714410
Ahmed, F., Ye, Q., Li, L., Ksebe, W., Wu, C., & Wang, K. (2026) · Worldviews on Evidence-Based Nursing · doi:10.1111/wvn.70095
Tabet, M. I., Vaughan‐Sarrazin, M., Lund, B. C., Fortis, S., Jalal, D. I., Misurac, J. M., & Griffin, B. R. (2026) · BMC Nephrology · doi:10.1186/s12882-026-04884-3
Mieles, D. F. Q., Castro, C. X. C., Castro, R. M. O., Leon, J. L. R., Santillán, A. R. J., Cruz, A. V. I. D. L., Vela, M. A. A., & Ulloa, I. R. G. (2026) · Imperium Académico Multidisciplinary Journal · doi:10.63969/r649gg24
Shingler, L., Tamhane, A., Chu, C.-M., Frey, J. A., Levitan, E. B., Judd, S. E., Bullen, A. L., Siew, E. D., Bonventre, J. V., Shlipak, M. G., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0331996
Self-citationWang, H. E., Frey, J. A., Tamhane, A., Shingler, L., Keister, A., Chu, C.-M., Levitan, E. B., Judd, S. E., Bullen, A. L., Siew, E. D., et al. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101466
Self-citationMeng, X., Wang, Y., Xiang, Y., Xu, X., Zhang, X., Wang, S., Tan, Z., Zhao, X., Wang, K., Li, M., et al. (2026) · Hypertension Research · doi:10.1038/s41440-026-02792-5
Komilova, B. I., Demyanova, K. A., Kozlovskaya, N. L., Олеговна, К. Е., Zhdanova, T. V., & Kobalava, Z. D. (2026) · Nephrology and Dialysis · doi:10.28996/2618-9801-2026-3-377-387
Debating targets for systolic blood pressure lowering in chronic kidney disease
Dounousi, E. C., Georgianos, P. I., & Agarwal, R. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag233
Metadata
- Authors
- Malhotra, R., Craven, T., Ambrosius, W. T., Killeen, A. A., Haley, W. E., Cheung, A. K., Chonchol, M., Sarnak, M., Parikh, C. R., Shlipak, M. G., & Ix, J. H.
- Affiliations
- University of California San Diego (US)
- Wake Forest University Health Sciences (US)
- University of Minnesota (US)
- Mayo Clinic in Florida (US)
- University of Utah (US)
- University of Colorado Denver (US)
- Tufts Medical Center (US)
- Yale University (US)
- San Francisco VA Medical Center (US)
- Corresponding author
- Ix, Joachim H.
- ORCID
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 73
- Issue
- 1
- Pages
- 21-30
- ISSN
- 0272-6386 (ISSN-L)
- PMC
- PMC7325694
- OpenAlex
- W2895157652
- Semantic Scholar
- 7d67f77b1830c29b36fa820e21fb195dbdb9ff18
- Cited by
- 132
- References
- 33
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 12 · 2023: 15 · 2022: 11 · 2021: 17 · 2020: 30 · 2019: 18
- FWCI
- 14.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Kidney Diseases (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK098234, K24DK110427)
- American Heart Association (14EIA18560026)
- NIH (HHSN268200900040C)
- National Heart, Lung, and Blood Institute (HHSN268200900046C)
- NIDDK (HHSN268200900047C)
- National Institute on Aging (HHSN268200900048C)
- National Institute of Neurological Disorders and Stroke (HHSN268200900049C)
- National Center for Advancing Translational Sciences of the NIH (UL1TR000439, UL1RR025755, UL1RR024134, UL1TR000003, UL1RR025771, UL1TR000093, UL1RR025752, UL1TR000073, UL1TR001064, UL1TR000050, UL1TR000005, 9U54TR000017-06, UL1TR000105-05, UL1TR000445, UL1TR000075, UL1TR000002, UL1TR000064, UL1TR000433, P30GM103337)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- intensive blood pressure lowering, chronic kidney disease, SPRINT trial, estimated glomerular filtration rate decline, urinary biomarkers, beta2-microglobulin, alpha1-microglobulin, uromodulin, KIM-1, neutrophil gelatinase-associated lipocalin, IL-18, MCP-1, renal inflammation, kidney repair, hemodynamic effects
- MeSH terms
- Aged, Aged, 80 and over, Female, Glomerular Filtration Rate, Humans, Hypertension, Kidney Tubules, Male, Middle Aged, Biomarkers, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
